Ribavirin Oral Product

DRUG2 trials

Sponsors

Zagazig University, Nanogen Pharmaceutical Biotechnology Joint Stock Company

Conditions

Chronic Hepatitis CHepatitis C

Phase 4

Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General Hospital

CompletedNCT06922643

Nanogen Pharmaceutical Biotechnology Joint Stock CompanyChronic Hepatitis C

Start: 2011-03-01End: 2013-03-01Updated: 2025-06-29

Unknown Phase

Determining the Sustained Virologic Response of Declatasvir in Egyptian Patients With Hepatitis C Virus Genotype 4

Zagazig UniversityHepatitis C

Start: 2017-11-01End: 2018-12-31Target: 250Updated: 2017-10-10